Stock Analysis
Clover Health Investments, Corp. (CLOV) Stock Analysis
Clover Health Investments, Corp. (CLOV) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Clover Health Investments, Corp. (CLOV) currently has an AIQ Score of 49/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Risk is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CLOV at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $4.82 |
| AIQ Score | 49/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.23B |
| P/E Ratio | 100.84 |
| Forward P/E | — |
| EPS | $0.05 |
| Revenue TTM | $743.17M |
| Dividend Yield | 0.00% |
| Beta | 2.49 |
| Volume | 4.49M |
| 52-week range | $1.58-$5.59 |
| RSI 14 | 82.21 |
| 50-Day SMA | $4.45 |
| 200-Day SMA | $3.18 |
| Analyst Price Target | $4.86 |
| Next Earnings | Nov 4, 2026 |
CLOV
OverviewCLOV Stock Analysis Summary
Clover Health Investments, Corp. (CLOV) currently has an AIQ Score of 49/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Risk resilience is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, CLOV has AIQ Score of 49/100 with Momentum base of 79/100 and fading Risk resilience at 36/100. Wait for component alignment before adding exposure.
Momentum (79/100) leads while Risk resilience (36/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.34% stock move · CLOV classified in Medical - Healthcare Plans.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CLOV Bullish or Bearish Right Now?
CLOV currently has a neutral overall setup. Momentum is the strongest factor at 79/100, while Risk Resilience is weakest at 36/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 79/100.
- - Price is +8.34% above its 50-day SMA.
- - Analyst target implies +0.83% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (35 vs 9).
- - Value is the current constraint at 42/100.
- - Risk Resilience is weak at 36/100.
Current Consensus
CLOV's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 1 neutral, and 9 sell votes. CLOV's 14-day RSI is 82.21, which places the stock in an overbought momentum range. CLOV's beta is 2.49, indicating greater market sensitivity than the broad market.
What Changed in CLOV?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the CLOV Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CLOV Decision Framework
Public evidence layers, setup checks, and risk context for Clover Health Investments, Corp..
Clover Health Investments, Corp. (CLOV) Stock Analysis
Clover Health Investments, Corp. has an AIQ Score of 49/100 in a Neutral regime. Momentum is strongest at 79/100. Beta is 2.49, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CLOV is in a Neutral AIQ regime with score 49/100. |
| Signal Conflict | The primary conflict is that momentum leads at 79/100 while risk lags at 36/100. |
| Factor Evidence | Momentum 79/100 · Value 42/100 · Quality 38/100 · Risk 36/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 79/100.
Momentum is 79/100 and RSI (14) is 82.2.
CLOV is in a Neutral regime at 49/100.
Risk factor is 36/100 with beta 2.49 and annual volatility 67.24%.
Current conflict: momentum leads at 79/100 while risk lags at 36/100.
CLOV Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CLOV Fundamentals
CLOV valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CLOV Technical Analysis
CLOV technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CLOV Stock Catalysts
Track CLOV earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CLOV Dividend Analysis
CLOV dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CLOV Financial Data
CLOV revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CLOV Risk Analysis
CLOV volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CLOV Stock News
CLOV stock news, market tone, recent headlines, and catalyst context.
CLOV vs Healthcare Services / Managed Care Peers
Current peer cohort: CLOV · CNC · COR · CVS · DGX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CLOV Current stock | 49/100 | 42/100 | 79/100 | 36/100 | 0.97 | 67.24% | Current |
| CNC Centene | 49/100 | 53/100 | 66/100 | 57/100 | 1.72 | 48.59% | CLOV vs CNC |
| COR Cencora | 55/100 | 62/100 | 60/100 | 59/100 | 0.3 | 31.54% | CLOV vs COR |
| CVS CVS Health | 51/100 | 70/100 | 55/100 | 53/100 | 0.84 | 30.62% | CLOV vs CVS |
| DGX Quest Diagnostics | 50/100 | 53/100 | 42/100 | 60/100 | 1.07 | 23.85% | CLOV vs DGX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CLOV
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CLOV
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CLOV Stock FAQ
What is CLOV stock price today?
Clover Health Investments, Corp.'s current stock price is $4.82. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CLOV bullish or bearish right now?
CLOV's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CLOV's market cap?
CLOV's market cap is $2.23B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CLOV's current P/E ratio?
CLOV's current P/E ratio is 100.84 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CLOV's RSI?
CLOV's 14-day RSI is 82.21 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CLOV above its 50-day and 200-day moving averages?
CLOV is 8.34% from its 50-day SMA and 51.35% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CLOV's next earnings date?
CLOV's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CLOV pay a dividend?
CLOV's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.